Tarsus Pharmaceuticals, Inc. TARS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$6.97M+16.8% | -$8.37M+33.5% | -$12.59M+38.1% | -$20.34M+19.0% | -$25.12M-8.7% | ||
| $197K-2.5% | $202K+1.0% | $200K0.0% | $200K-9.1% | $220K+14.6% | ||
| $11.97M-16.4% | $14.31M+16.9% | $12.24M+48.7% | $8.23M+18.8% | $6.93M-6.4% | ||
| $159K+1.9% | $156K+2.6% | $152K+4.1% | $146K+5.0% | $139K+0.7% | ||
| $30.29M+144% | $12.44M-12.9% | $14.29M— | —— | $15.67M-11.0% | ||
| $196K-63.4% | $536K— | $0-100% | $1.17M+1,290% | $84K— | ||
| -$9.25M-319% | $4.23M— | —— | —— | -$5.89M-231% | ||
| -$141K-137% | $381K+2.1% | $373K+466% | -$102K+18.4% | -$125K— | ||
| $13.24M+262% | -$8.19M-2.6% | -$7.98M-134% | $23.17M+366% | -$8.73M-213% | ||
| $240K-0.4% | $241K+20.5% | $200K0.0% | $200K-16.7% | $240K0.0% | ||
| -$189K-156% | $336K— | —— | $179K-58.3% | $429K+179% | ||
| -$24.65M— | —— | —— | -$29.39M-42.3% | -$20.65M+6.9% | ||
| $5.82M-8.5% | $6.36M+233% | $1.91M+90.8% | $1M+69.7% | $590K+719% | ||
| $126.8M+256% | $35.58M-65.2% | $102.33M-21.1% | $129.7M+3.3% | $125.57M+39.6% | ||
| -$58.56M— | —— | -$4.74M+90.8% | -$51.7M-48.0% | -$34.94M+41.3% | ||
| $0— | —— | —— | —— | $135.13M— | ||
| $1.2M-47.9% | $2.31M-9.8% | $2.56M+31.3% | $1.95M-98.6% | $136.56M+4,566% | ||
| -$82.01M-216% | $70.92M+341% | $16.08M— | —— | $80.97M+203% | ||
| $1.97M-4.3% | $2.06M-2.7% | $2.12M+1.1% | $2.09M+1.0% | $2.07M-4.6% | ||
| $1.93M— | —— | —— | —— | $0— | ||
| $849K-8.2% | $925K-39.7% | $1.53M-10.2% | $1.71M+30.1% | $1.31M-11.3% | ||
| $159K+1.9% | $156K+2.6% | $152K+4.1% | $146K+5.0% | $139K+0.7% | ||
| $240K-0.4% | $241K+20.5% | $200K0.0% | $200K-16.7% | $240K0.0% | ||
| $197K-2.5% | $202K+1.0% | $200K0.0% | $200K-9.1% | $220K+14.6% | ||
| -$9.25M-319% | $4.23M— | —— | —— | -$5.89M-231% | ||
| $7.71M— | —— | $23.84M+91.4% | $12.46M+989% | $1.14M— | ||
| $15.46M— | —— | —— | —— | $10.17M+7.6% | ||
| -$189K-156% | $336K— | —— | $179K-58.3% | $429K+179% | ||
| $13.24M+262% | -$8.19M-2.6% | -$7.98M-134% | $23.17M+366% | -$8.73M-213% | ||
| $77K-50.0% | $154K-24.9% | $205K+28.9% | $159K-3.0% | $164K-5.2% | ||
| $911K+2,747% | $32K-97.2% | $1.16M+279% | $305K+682% | $39K-4.9% | ||
| $0— | $0— | $0+100% | -$354K-200% | $354K+11,700% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $1.93M— | —— | —— | —— | $0— | ||
| -$30.47M— | —— | —— | -$30.39M-43.1% | -$21.24M+4.6% | ||
| -$30.47M— | —— | —— | -$30.39M-43.1% | -$21.24M+4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Tarsus Pharmaceuticals, Inc. generate?
- Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
- Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
